Open AccessAnti-Müllerian hormone as an ovarian reserve marker in women with the most frequent muscular dystrophies
Author(s) -
Olesja Parmová,
Eva Vlčková,
Monika Hulová,
Lívie Mensová,
Igor Crha,
Petra Strádalová,
Eva Kralickova,
Lenka Juříková,
Martina Podborská,
Radim Mazanec,
Ladislav Dušek,
Jiří Jarkovský,
Josef Bednařík,
Stanislav Voháňka,
Iva Šrotová
Publication year - 2020
Publication title -
medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.59
H-Index - 148
eISSN - 1536-5964
pISSN - 0025-7974
DOI - 10.1097/md.0000000000020523
Subject(s) - ovarian reserve , anti müllerian hormone , medicine , facioscapulohumeral muscular dystrophy , myotonic dystrophy , endocrinology , muscular dystrophy , hormone , gynecology , infertility , pregnancy , biology , genetics
Abstract Some muscular dystrophies may have a negative impact on fertility. A decreased ovarian reserve is 1 of the factors assumed to be involved in fertility impairment. AMH (anti-Müllerian hormone) is currently considered the best measure of ovarian reserve. A total of 21 females with myotonic dystrophy type 1 (MD1), 25 females with myotonic dystrophy type 2 (MD2), 12 females with facioscapulohumeral muscular dystrophy (FSHD), 12 female carriers of Duchenne muscular dystrophy mutations (cDMD) and 86 age-matched healthy controls of reproductive age (range 18 – 44 years) were included in this case control study. An enzymatically amplified 2-site immunoassay was used to measure serum AMH level. The MD1 group shows a significant decrease of AMH values (median 0.7 ng/mL; range 0 – 4.9 ng/mL) compared with age-matched healthy controls ( P < .01). AMH levels were similar between patients and controls in terms of females with MD2 ( P = .98), FSHD ( P = .55) and cDMD ( P = .60). This study suggests decreased ovarian reserve in women with MD1, but not in MD2, FSHD and cDMD.